Grace Therapeutics, Inc. (GRCE) Financials

GRCE Assets vs Liabilities
DateAssetsLiabilities
June 30, 2026 50.1 million 1.9 million
March 31, 2026 66.7 million 2.8 million
Dec. 31, 2025 68.5 million 3.6 million
Sept. 30, 2025 66.6 million 3.8 million

GRCE Free Cash Flow and Stock based compensation
Graph available only for paid members. Upgrade to see it.
DateFree Cash FlowStock based compensation
June 30, 2026 -3.2 million 105000
March 31, 2026 -1.7 million -24000
Dec. 31, 2025 -2.2 million 314000
Sept. 30, 2025 -3.2 million 206000

GRCE Net Income

No data available :(

GRCE Cash and Debt
Graph available only for paid members. Upgrade to see it.
DateCashDebtCapital Lease
June 30, 2026 13.8 million - -
March 31, 2026 17.0 million - -
Dec. 31, 2025 18.7 million - -
Sept. 30, 2025 16.9 million - -

GRCE Shares Outstanding
Graph available only for paid members. Upgrade to see it.
DateShares Outstanding
June 30, 2026 17.3 million
March 31, 2026 16.5 million
Dec. 31, 2025 16.9 million
Sept. 30, 2025 15.9 million

GRCE Expenses
Graph available only for paid members. Upgrade to see it.
DateCapexR&DG&AS&M
June 30, 2026 - 697000 1.7 million -
March 31, 2026 - 420000 308589 -
Dec. 31, 2025 - 633924 2.7 million -
Sept. 30, 2025 - 792206 2.7 million -

GRCE Cost of Revenue
Graph available only for paid members. Upgrade to see it.
DateRevenueCost of Revenue
June 30, 2026 - -
March 31, 2026 - 2000
Dec. 31, 2025 - 4116
Sept. 30, 2025 - 2000

GRCE

Price: $1.89

52 week price:
1.79
5.18

Earnings Per Share: -1.17 USD

Exchange: NCM

Sector: Healthcare

Industry: Biotechnology

Market Capitalization: 33.6 million

Links: